1. Home
  2. BXC vs ADCT Comparison

BXC vs ADCT Comparison

Compare BXC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluelinx Holdings Inc.

BXC

Bluelinx Holdings Inc.

HOLD

Current Price

$77.79

Market Cap

502.3M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.87

Market Cap

484.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXC
ADCT
Founded
2004
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
502.3M
484.4M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
BXC
ADCT
Price
$77.79
$3.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$88.67
$7.60
AVG Volume (30 Days)
88.4K
656.4K
Earning Date
02-18-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.71
N/A
Revenue
$2,948,840,000.00
$75,209,000.00
Revenue This Year
$0.63
$12.48
Revenue Next Year
$3.06
$5.12
P/E Ratio
$45.89
N/A
Revenue Growth
N/A
6.35
52 Week Low
$52.71
$1.05
52 Week High
$106.01
$4.80

Technical Indicators

Market Signals
Indicator
BXC
ADCT
Relative Strength Index (RSI) 62.73 53.45
Support Level $66.38 $3.88
Resistance Level $80.34 $4.10
Average True Range (ATR) 3.16 0.27
MACD 0.40 0.03
Stochastic Oscillator 85.44 67.20

Price Performance

Historical Comparison
BXC
ADCT

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: